Full-Service CDMO for a Global Market

CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization.

With scientific expertise and partnership at its core, CordenPharma provides customers high-value, end-to-end services with a strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid NanoParticles, sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent and Regular Potency).

The CordenPharma Group is comprised of 12 facilities across Europe and North America. In the 2022 financial year, the organization generated sales of 870 million Euros and had over 3,000 employees.


CordenPharma Mission

CordenPharma is a full-service partner in the cGMP Contract Development & Manufacturing of Active Pharmaceutical Ingredients (APIs), Excipients, Drug Products and Pharma Packaging Services, supporting leading pharmaceutical & biotechnology companies to achieve product success for their patients’ healthier lives.


CordenPharma Acquisition History

CordenPharma Facility Legacy Company Year Acquired
CordenPharma Chenôve Abbott / Solvay 12 / 2007
CordenPharma Plankstadt AstraZeneca 1 / 2008
CordenPharma Caponago AstraZeneca 6 / 2009
CordenPharma Switzerland Sanofi / Genzyme 2 / 2011
CordenPharma Colorado Roche 8 / 2011
CordenPharma Bergamo Tessenderlo / Farchemia 12 / 2012
CordenPharma Brussels Solvay / Peptisyntha 11 / 2013
CordenPharma Boulder Pfizer / Hospira 10 / 2017
CordenPharma Ettingen Vifor Pharma 2 / 2022
CordenPharma Fribourg Vifor Pharma 2 / 2022
CordenPharma Lisbon Vifor Pharma 2 / 2022